跳至主要内容
临床试验/NCT02288845
NCT02288845已完成2 期

An Open-Label Positron Emission Tomography (PET) Study to Demonstrate Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of ITI-007 in Stable Schizophrenia Patients

Intra-Cellular Therapies, Inc.1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2014年10月最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
入组人数
14
试验地点
1
主要终点
Brain Receptor Occupancy as Measured by Positron Emission Tomography

研究概览

简要总结

The purpose of this study is to determine the relationship between ITI-007 dose, plasma levels and brain receptor occupancy in patients with stable schizophrenia.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with schizophrenia who are drug-free with regard to their antipsychotic medication
  • In clinical remission and free from acute exacerbation of their psychosis
  • In good health

排除标准

  • Clinically significant medical conditions considered inappropriate for trial participation

研究组 & 干预措施

ITI-007

Experimental

ITI-007 formulated capsule will be administered orally once daily for up to 14 days in up to 14 subjects.

干预措施: ITI-007 (Drug)

结局指标

主要结局

Brain Receptor Occupancy as Measured by Positron Emission Tomography

时间窗: Up to 14 days

次要结局

  • Safety and Tolerability as Measured by Number of Participants with Adverse Events(Up to 14 days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Receptor Occupancy of ITI-007 Using Positron... | 临床试验